Biotech Beat Nvidia in 2025. Can It Do It Again?

In this podcast, Motley Fool analysts Karl Thiel, Tom King, and Tim Beyers discuss:

• Slow rolling chaos at the FDA and its effects on drug approvals.
• How to think about risk when investing in biotech.
• A review of results from DNA researcher Twist Bioscience.

Don't wait! Be sure to get to your favorite bookseller and pick up a copy of David's Gardner's new book, Rule Breaker Investing: How to Pick the Best Stocks of the Future and Build Lasting Wealth.

To catch full episodes of all The Motley Fool's free podcasts, check out our podcast center. When you're ready to invest, check out this top 10 list of stocks to buy.

A full transcript is below.

This podcast was recorded on Feb. 02, 2026.

Tim Beyers: Is Biotech getting unfairly ignored? You're listening. Motley Fool money. Welcome fools. I'm your host, Tim Beyers, and with me are two of my longtime Rule Breakers teammates, Karl Thiel and Tom King. Thanks for being here, guys.

Karl Thiel: Yeah, it's great to be here.

Tom King: Good to be here.

Tim Beyers: We're going to preview some biotech earnings. We're also going to check in on one that reported this morning, and we're going to paint a picture of an industry that probably deserves a little bit more love, a little bit more attention. Get your coffee ready because it's biotech time. Let's talk about biotech approvals, Carl, and what's going on at the FDA, because it does seem as though things are a little bit, let's call it turbulent.

Karl Thiel: Let me just paint a little quick background here which is that 2025 was an absolutely tremendous year for the industry. I don't know if many people realized this, but biotech as a whole, the XBI, for instance, outperformed NVIDIA in 2025. It was a very strong year after a very, very long, bleak period. I do think there's actually a lot of enthusiasm continuing into 2026, but I don't know what it is about me, Tim. I got to throw cold water on stuff. I just want to sound, there's a few alarm bells or a few flags out there that I think are interesting and that people need to be aware of. One of them is the continuing chaos I guess, that we're seeing at FDA for want of a better word.

Tim Beyers: Well, it does seem as though there was a warning from one of a former senior executive here. I think this man's name is Richard Pasdur who is the former longtime head of the oncology division. I've often heard you talk about the JP Morgan conference, Carl, and how important it is to the biotech industry, but it sounds like he had some spicy things to say at that conference.

Karl Thiel: Yeah, he did. This is just a couple of weeks ago in mid January. I mean, he wasn't just the head of oncology. He is one of five people who headed up Cedar, the main drug approval division. Extremely senior position at FDA, one of five people who did that during 2025 because there was so much turnover in the role. One of the things that he told the Big Pharma people at the conference was that he was worried that the firewall between political appointees and drug reviewers has been breached was his quote. That the pharma industry is continuing to underestimate the damage that's already been done. Now, you can certainly dismiss that as the thoughts of a long serving bureaucrat who doesn't like the changes that he's seen at the industry. But what he called chaos and whether that's the results of just turnover or politics or anything else going on, does seem to describe some of the seemingly contradictory approaches that we've been seeing to regulation recently.

Tim Beyers: I mean, there what's interesting here is that and especially when you say that, it makes me wonder that some of the companies we would look at for the biotech side of the scorecard and rule breakers that are dependent upon the FDA for fast approvals of promising drugs that are in clinical trials. Then suddenly there's a bit of maybe some extra risk here. Can you talk me through, when he's talking about that, is he talking about longer approval cycles? Is he talking about inconsistent approvals? What's the risk here for companies that we follow?

Karl Thiel: We can think about it as just trying to read the tea leaves on how the agency is going to regard various submissions. I think you have these two different themes going. One is that under Marty Makary, the current commissioner of FDA, he has been very, very forward looking about how he wants to speed approvals, how he wants to make this easier for industry. That's something that industry is super enthusiastic about. That includes everything. There's been talk about doing less animal testing. There's been talking about having easier standards for rare diseases where you can basically get on the market for with a single study, as long as you have some confirmatory evidence which would make that faster and easier. There's been talk about a plausible mechanism pathway, basically, where the agency could approve drugs based on limited clinical data, basically, if the biology makes sense. Think about it, it's like, if you have a disease that's marked by an enzyme deficiency and you give them the enzyme, that makes sense that that would work. When you have that plausible mechanism, you can take basically less data to support it. These are all things that industry is super excited about. The thing is, there's an operating reality on the ground that seems to be coming out differently than that. That's where I think there's a lot of confusion right now because in some ways, the FDA actually seems to be raising the bar on rare disease rather than lowering it. We've seen that come out in a few different ways.

Tim Beyers: Well, let's talk about those. I would love a couple of examples here because what we want to understand as investors is do we need to be more careful about the types of biotech companies we're looking at here because what we thought would be a reasonable approval cycle is no longer. What are some examples of what we're seeing in the industry right now?

Karl Thiel: Yeah. You said what types of products or what types of approvals. I think that's a very good point right there. A lot of controversy seems to come particularly around things that go through the Seber, the biologics division, the cell gene therapies and cell therapies, things in that space seem to be particularly unpredictable right now. We just saw that this past week, a company called Regenxbio was expecting approval of a drug on February 8th for a disease called Hunter syndrome. That's almost certainly not going to happen now. What's interesting is that it's because a different drug, a different gene therapy had a complication come up in clinical trials that basically they found a tumor that had developed in somebody that had been treated with the drug four years ago and so they put it on clinical hold to investigate that further. I want to point out these are bad, fatal diseases. There's some tolerance for side effects and bad outcomes and stuff with therapies when you're addressing a fatal, rare genetic disease. This was a benign tumor, but a tumor, nonetheless, it developed in somebody had been treating four years earlier. Unclear if it's related to the gene therapy itself, but certainly a red flag and putting it on hold to investigate that is called for. That's the right call. What's weird is that they put another drug that is just about to get approval, supposedly, on hold because it's similar. There was no evidence of problems in that. It uses a somewhat different vector. I mean, all these things use slightly different vectors, even if they're all technically in the same class. It seems to contradict what FDA had been saying previously which is that they were going to be more tolerant of these fatal, rare diseases, and that's not what we're seeing.

Tim Beyers: Last point on this or last question, I guess, I should say, before we move on to our next section here. But does this make you raise the bar for what we would consider a reasonable biotech investment and say, rule breakers, do we need a bit more development, like a biotech company that's more mature before they make it to the score card, or does this really not change anything?

Karl Thiel: I think that you have to realistically put extra risk around anything in the gene therapy cell therapy space. I mean, we're just seeing that. We've seen it too many times at this point to not recognize that. I still think there are some really, really interesting possibilities in that space, but you have to maybe build in extra timelines for more questions for things being delayed and stuff like that, unfortunately. On the other hand, we may finally start to see some things get sped up, and we can talk about that a little bit, maybe in our next segment.

Tim Beyers: Tom, any thoughts on this? Does it make you more or less interested in biotech to bring to the scorecard?

Tom King: I think Karl said it pretty well. I think we've seen the current skepticism around vaccines and mRNA based therapies. I think Carl put it pretty well. You just got to factor that into your risks when you consider the sector and those particular subsectors within the biotech industry.

Tim Beyers: Still like biotech. Maybe lengthen your timeline for how long you're going to stay invested in these companies. Up next, we're going to do some Biotech earnings predictions. Stay tuned. You're listening to Motley Fool Money.

ADVERTISEMENT: Could AI help you do more of what you love? Workday is the next gen ERP powered by AI that actually knows your business. We help you handle the have to dos, so you can focus on the can't wait to dos. It's a new workday.

Tim Beyers: We are back with Karl Thiel and Tom King. I'm Tim Beyers, and let's start with some earnings predictions here. We've got some big names that are reporting this week guys, and I'm going to start with Eli Lilly, Ticker, LLY. I'll give you some of the background on this. This is a big company, and they have, like for some others, we're going to get into another one here. But weight loss rugs. Oh, boy, that has been a big driver for Lily. Earnings per share, consensus estimate. A range of $6.99 to $7.86. The consensus estimate is $7.48, revenue of 17.85 billion. Roughly I mean, this is over 30% relative earnings growth year over year. So big numbers here. Tom, I'll start with you. Are you expecting a beat, a raise, or a miss for Eli Lilly in its upcoming quarter here? They're going to report, I believe on the fourth, so Wednesday this week. What do you think?

Tom King: I'm going to go with the beat because I think that guidance is always arranged so that it's possible easy to more likely to beat. That would be my guess.

Tim Beyers: Yeah, so low bar. Set the low bar and leap over it. Carl, I mean, when you look at the Lily business, I mean, I assume it's way, way bigger than just weight loss drugs. But is this the weight loss trade? Is that what Lily is?

Karl Thiel: Yeah, it effectively is. First of all, I just have to say, by the way, I love that you're referring to Lily as a biotech company. That's such a victory for biotech is like a century old big pharma company. But it's true. I mean, it's like these GOP-1 drugs, they are biotech drugs, and they are in the driver's seat right now. Yeah, I would put Lily down for a beat. I think they've beaten in the last three or four quarters. I think they're in a super strong position right now. They'd probably a decent candidate to raise, too. The only sort of question mark right now is that CVS pharmacies took tirzepatide, which is the active ingredient in both Zep bound and Mongio. They took that off their formulary last summer, and you saw a little bit of a ripple of it in the third quarter, but this fourth quarter is when we're really going to see if that makes a difference or not because there were some people switching over to semaglutide after that happened and that could have some impact, but I think they'll be able to drown that out.

Tim Beyers: Fair enough. We've got two beats for Eli Lilly. Moving on. We're going to move on to Novo Nordisk. Another one, I think that's in the weight loss trade for lack of better term here. Ticker NVO. They are also reporting on Wednesday 4th, so Tom will come back to you and give you some numbers here. So the earnings per share expectations are between 89 and 0.90 a share. That's versus $0.91 in Q4 of last year. Flat to slightly down revenue of 11.96 billion and there is the possibility of a dividend coming into this quarter. What do you think? Beat, raise, or miss. I will ask you, what do you put the odds for a dividend from Novo Nordisk coming to this quarter? Do you have any thoughts on the odds?

Tom King: Well, in terms of the possibility of a Miss, I would probably put that a little bit higher than, than for Eli Lilly. Novo Nordisk has been on the back for a little bit, the last couple of years. They've got a new CEO. Things haven't been they've been having some struggles with various things. Just for that reason, I would rank the possibility of a MIS slightly higher. The same logic applies to the initiation of that dividend. I'm guessing that in a time of uncertainty for them, they'd rather hang on to the cash. I would say that's probably unlikely, but there may well be more to it than that.

Tim Beyers: Less than 50% is what I hear you saying?

Tom King: Yeah, sure.

Tim Beyers: Yeah. Carl, beat, raise, or miss, and I'll put the dividend question to you this way, given that Novo Nordisk has been a little shakier as Tom points out, is the dividend what you do to stabilize things among the investors or is it like, let's conserve the cash and go again?

Karl Thiel: I think they would frame it a little bit differently. They have a new CEO, the first non Danish CEO in their company's history, who's already signaled that he's going to go big on acquisitions which also, by the way, I think they need to do that. Novo Nordisk has been traditionally very, very shy about doing M&A, and I think that would be a good move for them. But that does make the timing of introducing a dividend a little more questionable to me. I would lean toward no on that. Then for the earnings, they've already cut guidance twice I think in the last year. I'm looking for them to hopefully meet. It'd be great to see them beat. I do think they're due for relief at some point, but yeah, I'm a meet or maybe slightly ahead. I'd like to see a lot is riding on obviously their oral Wegovy launch. That's very recent, so it's a little hard for it to move the needle to too much, but it will certainly play into their guidance going forward for the rest of the year. But the numbers for oral Wegovy have been strong.

Tim Beyers: We've got a miss and maybe a slight beat or meet. Let's move on to Twist Bioscience which is a company that we've looked at multiple times in Rule Breakers. Tom, I'm going to come to you because as we're recording, this is Monday morning, we got results. They did provide some preliminary results. Ticker TWST on January 12th and now we have the real results. Let me ask you, were you surprised? Were you delighted? What did you see?

Tom King: Well, for the quarter, it was pretty much what they said it would be. It was 104 million in revenue for the first quarter of 2026, which ended December 31st, 2025, which is pretty much exactly what they had said it would be when they announced their preliminary results on January 12th. Still unprofitable, but get in better. The bigger picture here is more interesting for me though, the longer term trend in twist biosciences. It's a company that first crossed my radar I think in 2020. Basically, what Twist does is they make DNA for other people. You're a researcher, you say to Twist, please make this DNA with this code of nucleotides, and they do that. The researcher then puts it into a cell and sees what it does. They heavily are dependent on the level of research activity. As we know and Carl has said earlier in the show, we've been through what you might call a bit of a biotech winter the last few years. There's been a fair amount of pessimism in industry, lack of investment, and so on. But what impressed me about Twist when I looked over the longer term results is that they've consistently grown revenue through this period from 2020 through last year, adding about 60 million in revenue per year. Their rate of cash burn has gone down. They're still burning through cash, but it's getting a lot less. I would say from a business perspective, it's doing all the right things, it's maintained its revenue growth, it's reduced its cash consumption, it's getting toward profitability. The results they released this morning pretty much confirmed that the trend that has played out over the last five years is continuing satisfactorily. Yeah, it's still an interesting company, it's a lot cheaper than it was it one point in the 2020, 2021 period, it traded an eye watering 111 times revenue, multiple. It subsequently reached a low of three times revenue in May of 2023, it would probably translate to a 95% loss decline. Now it's at a more reasonable seven times. Yeah, interesting company.

Tim Beyers: Carl, let me just ask you very quickly on this, and then we'll move to our final segment. But because this is a company that's in DNA research, is some of the chaos you talked about at FDA, does it apply to a company like Twist? Are they caught in that web of chaos?

Karl Thiel: Only indirectly. I mean, they're not really working with FDA directly. They're working with companies who are trying to discover new drugs. They're insulated from it. Yeah, just tremendous technology. It was a great beaten rays quarter. Hopefully they'll continue to have good things happen.

Tim Beyers: There you go. That's Eli Lilly, Ticker LLY, Novo Nordisk, Ticker NVO, and Twist Bioscience, which reported this morning a good beaten raise. Up next, we're going to preview tomorrow's show. Thanks for tuning in. You are listening to Motley Fool Money.

ADVERTISEMENT: The world moves fast. You workday, even faster. Pitching products, drafting reports, analyzing data. Microsoft 365 copilot is your AI assistant for work built into Word, Excel, PowerPoint, and other Microsoft 365 apps you use, helping you quickly write, analyze, create, and summarize so you can cut through clutter and clear a path to your best work. Learn more at miicrosoft.com slash 365 copilot.

Tim Beyers: We are back with our final segment here, a preview for tomorrow when Emily Flippen, Jason Hall, and Lauren Hurst will be talking about AI and gaming. They are going to talk about Project Genie, which if you have not heard of this, is an AI model designed specifically for creating 3D worlds. That sounds interesting. Honestly, a little bit terrifying, but it'll be Emily, Lauren, and Jason, so please stay tuned for that. There are also a lot of biotech earnings that are coming this week, so please stay tuned for that at the site. We will have coverage every day for all of the stocks you are following in your portfolio. Karl, Tom, thanks for joining me today. Appreciate it. Good chance to talk some more biotech. Please come back to do this again. People on the program may have interest in the stocks they talk about, and the Motley Fool may have formal recommendations for or against, so don't buy or sell stocks based solely on what you hear. All personal finance content follows Motley Fool editorial standards and is not approved by advertisers. Advertisements are sponsored content and provided for informational purposes only. To see our full advertising disclosure, please check out our show notes. That's it for today's Motley Fool Money. Thanks for tuning in. Our engineer today is Dan Boyd. Our producer is Anand Chokkavelu. I'm Tim Beyers. Thanks to Tom King and Carl Teal for being with me today. Fools, we will see you again tomorrow. Thanks again and Fool on.

Karl Thiel has positions in Nvidia and Regenxbio. Thomas King, CFA has positions in SPDR Series Trust-SPDR S&P Biotech ETF and Twist Bioscience. Tim Beyers has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Nvidia, Regenxbio, and Twist Bioscience. The Motley Fool recommends CVS Health, Novo Nordisk, and SPDR Series Trust-SPDR S&P Biotech ETF. The Motley Fool has a disclosure policy.